RT1640 is made up of three small molecule drugs that together synergize to act on three distinct pathways in hair biology. One drug promotes the growth and migration of new stem cells, one drug promotes the commitment of the follicular stem cells to become new hair and one protects the dermal papilla from the effects of DHT. RT1640 has been formulated to enhance penetration through the skin, to make it available to the hair follicles.
Two of the three active agents in RT1640, cyclosporine A and Minoxidil, are FDA approved and off patent. They are known to be safe for use on the skin, and there are thousands of people-year exposures to these drugs. The third active ingredient in RT1640, is a new chemical entity (NCE) called RT175. Created by one of the RiverTown co-founders, it has been tested in over 600 humans in FDA sanctioned clinical trials. RT175 has an outstanding safety profile, with no serious adverse events associated with its use.
Complete reversal of AGA over 3 months. The subject is a 42 yo. male with AGA or 2 years duration
In spite of AGA being known as “male pattern baldness” its incidence is not restricted to men. Sixty-five percent of women over the age of 65 years old also develop AGA. Our data to date demonstrate that RT1640 is as effective in women as it is in men.
RT1640 promotes hair restoration